Results 241 to 250 of about 204,688 (384)
PharmGKB summary: cyclosporine and tacrolimus pathways
Julia M. Barbarino+4 more
semanticscholar +1 more source
This cohort study of 1793 atopic dermatitis patients (aged ≥ 12) found higher infection rates with Janus kinase inhibitor treatment compared to biologic treatment, particularly for herpes infections, with a history of viral or fungal skin infection as a risk factor associated with infection.
Lian F. van der Gang+22 more
wiley +1 more source
Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Following Initiation of Sulfasalazine for Ulcerative Colitis: A Yearlong Clinical Challenge. [PDF]
Andrews MB, Patrone MV, Bickston SJ.
europepmc +1 more source
Increased cyclosporine uptake by cells pretreated with FK506 and evidence for binding of both drugs to a common intracellular protein [PDF]
Diven, WF+4 more
core
EFFECT OF CYCLOSPORINE AND DELAYED GRAFT FUNCTION ON POSTTRANSPLANTATION ERYTHROPOIESIS
Anatole Besarab+6 more
openalex +1 more source
Successful treatment of palmoplantar pustulosis with topical ruxolitinib
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Neda Cramer+3 more
wiley +1 more source
Cadaveric Renal Transplantation in Diabetics in the 1980's: with Special Reference to Cyclosporine. [PDF]
Hakala, Thomas B+4 more
core
Psoriasis affects 2–3% of the population, with numerous biologic options complicating treatment selection. This real‐world study found IL‐23p19 inhibitors offer the longest‐lasting effectiveness and safety. Psoriatic arthritis reduced ustekinumab survival, and prior biologic use impacted persistence, especially for IL‐17 inhibitors.
Leila Motedayen Aval+8 more
wiley +1 more source